B Calkins / Shutterstock.com
Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board (PTAB) not to institute an inter partes review (IPR) petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Acorda; PTAB; Coalition for Affordable Drugs; Securities Exchange Commission; Ampyra; Kyle Bass; IPR